title: Clinical and pharmacotherapeutic relevance of the double-chain domain of the angiotensin II type 1 receptor blocker olmesartan.
abstract: We previously reported that the angiotensin II type 1 (AT(1)) receptor blocker (ARB) olmesartan has two important interactions to evoke inverse agonism (IA). We refer to these interactions as the "double-chain domain (DCD)." Since the clinical pharmacotherapeutic relevance of olmesartan is still unclear, we examined these effects in rats and humans. We analyzed the effects at an advanced stage of renal insufficiency in Dahl salt-sensitive hypertensive rats (Study 1). Rats were fed a high-salt diet from age 9 weeks and arbitrarily assigned to three treatment regimens at age 16 to 21 weeks: olmesartan (2 mg/kg/day) with DCD, a compound related to olmesartan without DCD (6 mg/kg/day, R-239470) or placebo. We also compared the depressor effects of olmesartan to those of other ARBs in patients with essential hypertension (Study 2). Thirty essential hypertensive outpatients who had been receiving ARBs other than olmesartan were recruited for this study. Our protocol was approved by the hospital ethics committee and informed consent was obtained from all patients 12 weeks prior to switching from ARBs other than olmesartan to olmesartan. In Study 1, olmesartan induced a more prominent suppression of the ratio of urinary protein excretion to creatinine at age 21 weeks without lowering blood pressure among the three groups. In Study 2, the depressor effect of olmesartan was significantly stronger than those of other ARBs, which do not contain the DCD. These additive effects by olmesartan may be due to DCD.
authors.affiliation: Department of Cardiology, Fukuoka University School of Medicine, Jonan-Ku, Fukuoka, Japan.
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Kiya
authors.forename: Shin-Ichiro
authors.initials: S
authors.lastname: Miura
authors.forename: Masahiro
authors.initials: M
authors.lastname: Fujino
authors.forename: Satoshi
authors.initials: S
authors.lastname: Imaizumi
authors.forename: Sadashiva S
authors.initials: SS
authors.lastname: Karnik
authors.forename: Keijiro
authors.initials: K
authors.lastname: Saku
mesh_terms: D000368:Aged; D047228:Angiotensin II Type 1 Receptor Blockers / Q000737:chemistry* / Q000494:pharmacology*; D000818:Animals; D001665:Binding Sites; D001794:Blood Pressure / Q000187:drug effects; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006860:Hydrogen Bonding; D006973:Hypertension / Q000188:drug therapy / Q000503:physiopathology; D007093:Imidazoles / Q000737:chemistry* / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D008958:Models, Molecular; D051381:Rats; D020303:Rats, Inbred Dahl; D044140:Receptor, Angiotensin, Type 1 / Q000737:chemistry / Q000187:drug effects*; D051436:Renal Insufficiency, Chronic / Q000517:prevention & control; D055672:Static Electricity; D013777:Tetrazoles / Q000737:chemistry* / Q000494:pharmacology*
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D007093:Imidazoles; D044140:Receptor, Angiotensin, Type 1; D013777:Tetrazoles; C437965:olmesartan